{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:08:29Z","timestamp":1773853709477,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 1194694"],"award-info":[{"award-number":["GNT 1194694"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lanwpc.2025.101754","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:42:07Z","timestamp":1764204127000},"page":"101754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data and key evidence gaps"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-8986","authenticated-orcid":false,"given":"Amanda","family":"Gwee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-6524","authenticated-orcid":false,"given":"Sarah","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Best","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiera","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2404-4830","authenticated-orcid":false,"given":"Alice","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Lutui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Mostaghim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Voss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-4311","authenticated-orcid":false,"given":"Heather","family":"Weerdenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-0594","authenticated-orcid":false,"given":"Phoebe","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-612X","authenticated-orcid":false,"given":"Daniel","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.lanwpc.2025.101754_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanwpc.2025.101754_bib2","series-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101754_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S2352-4642(24)00048-8","article-title":"Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics","volume":"8","author":"Bamford","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2471\/BLT.19.235309","article-title":"Global sales of oral antibiotics formulated for children","volume":"98","author":"Li","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101754_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1473-3099(19)30214-2","article-title":"Hard to study, hard to treat: putting children at the centre of antibiotic research and development","volume":"19","author":"Balasegaram","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101754_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2352-4642(20)30365-5","article-title":"Harmonising regulatory approval for antibiotics in children","volume":"5","author":"Williams","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002418","article-title":"Antimicrobial resistance in the Pacific Island countries and territories","volume":"5","author":"Loftus","year":"2020","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.lanwpc.2025.101754_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-8603-9-34","article-title":"Key informant interview on antimicrobial resistance (AMR) in some countries in the Western Pacific region","volume":"9","author":"Lee","year":"2013","journal-title":"Global Health"},{"issue":"10369","key":"10.1016\/j.lanwpc.2025.101754_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101754_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijantimicag.2005.11.004","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus infections","volume":"27","author":"Maltezou","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciab510","article-title":"Pediatric Staphylococcus aureus bacteremia: clinical spectrum and predictors of poor outcome","volume":"74","author":"Campbell","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2025.101754_bib12","article-title":"AGAR kids report: 2020 and 2021 surveillance outcome programs \u2013 bloodstream infections from patients <18 years, January 2020 \u2013 December 2021","volume":"48","author":"Williams","year":"2024","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.lanwpc.2025.101754_bib13","series-title":"Antimicrobial resistance in bacteraemia isolates from pediatric patients in Australia, 2013-2021: an AGAR-KIDS report","author":"Williams","year":"2023"},{"issue":"10","key":"10.1016\/j.lanwpc.2025.101754_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapediatrics.2016.1477","article-title":"Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children","volume":"170","author":"McMullan","year":"2016","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.lanwpc.2025.101754_bib15","series-title":"Annual survey of methicillin-resistant Staphylococcus aureus (MRSA)","author":"Heffernan","year":"2017"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib16","article-title":"Antibiotic resistance in Pacific Island countries and territories: a systematic scoping review","volume":"8","author":"Foxlee","year":"2019","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"10.1016\/j.lanwpc.2025.101754_bib17","first-page":"8361","article-title":"Methicillin-resistant Staphylococcus aureus in Melanesian children with haematogenous osteomyelitis from the Central Highlands of Papua New Guinea","volume":"6","author":"Aglua","year":"2018","journal-title":"Int J Pediatr"},{"key":"10.1016\/j.lanwpc.2025.101754_bib18","article-title":"Antimicrobial susceptibility of bacterial isolates from clinical specimens in four Pacific Island countries, 2017-2021","volume":"32","author":"Loftus","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanwpc.2025.101754_bib19","article-title":"The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019-2022","volume":"45","author":"Getahun Strobel","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.spid.2006.06.006","article-title":"Enterococcal infection in children","volume":"17","author":"Butler","year":"2006","journal-title":"Semin Pediatr Infect Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90535-6","article-title":"Clinical characteristics and prediction analysis of pediatric urinary tract infections caused by gram-positive bacteria","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanwpc.2025.101754_bib22","series-title":"Australian Enterococcus Surveillance Outcome Program (AESOP) Bloodstream Infection Report: 2022 final report","year":"2022"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib23","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0134","article-title":"Clinical management of Staphylococcus aureus bacteremia in neonates, children, and adolescents","volume":"146","author":"McMullan","year":"2020","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101754_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00059-22","article-title":"Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections","volume":"36","author":"Cairns","year":"2023","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.lanwpc.2025.101754_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jpids\/piab027","article-title":"Clinical practice guideline by the Pediatric Infectious Diseases society and the Infectious Diseases society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics","volume":"10","author":"Woods","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving Daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101754_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on Daptomycin plus Ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101754_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40272-021-00468-w","article-title":"Ceftaroline fosamil for treatment of pediatric complicated skin and soft tissue infections and community-acquired pneumonia","volume":"23","author":"Esposito","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40261-017-0523-2","article-title":"Current clinical trials on the use of ceftaroline in the pediatric population","volume":"37","author":"Corey","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0000000000003798","article-title":"The safety and efficacy of Dalbavancin and active comparator in pediatric patients with acute bacterial skin and skin structure infections","volume":"42","author":"Giorgobiani","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.clinthera.2015.04.008","article-title":"Clinical outcomes of daptomycin for vancomycin-resistant enterococcus bacteremia","volume":"37","author":"Moise","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101754_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2016.02.006","article-title":"Vancomycin-Resistant enterococci: therapeutic challenges in the 21st century","volume":"30","author":"Miller","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jhin.2013.07.007","article-title":"Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria","volume":"85","author":"Khair","year":"2013","journal-title":"J Hosp Infect"},{"issue":"11","key":"10.1016\/j.lanwpc.2025.101754_bib35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1592\/phco.30.11.1136","article-title":"Vancomycin-resistant enterococcal urinary tract infections","volume":"30","author":"Heintz","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101754_bib36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/infdis\/163.5.951","volume":"163","year":"1991","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/clinids\/13.3.397","article-title":"Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer","volume":"13","author":"Viscoli","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101754_bib38","first-page":"275","article-title":"Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial","volume":"2","author":"Pico","year":"1993","journal-title":"Eur J Med"},{"issue":"11","key":"10.1016\/j.lanwpc.2025.101754_bib39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/INF.0b013e3182a26774","article-title":"A randomized controlled trial of a vancomycin loading dose in children","volume":"32","author":"Demirjian","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib40","first-page":"308","article-title":"Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial","volume":"112","author":"Ceriani Cernadas","year":"2014","journal-title":"Arch Argent Pediatr"},{"issue":"12","key":"10.1016\/j.lanwpc.2025.101754_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01102-19","article-title":"Early Bayesian dose adjustment of vancomycin continuous infusion in children: a randomized controlled trial","volume":"63","author":"Berthaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101754_bib42","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2179","article-title":"Continuous versus intermittent vancomycin infusions in infants: a randomized controlled trial","volume":"143","author":"Gwee","year":"2019","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S2352-4642(21)00305-9","article-title":"Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial","volume":"6","author":"Hill","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"Suppl 2","key":"10.1016\/j.lanwpc.2025.101754_bib44","first-page":"19","article-title":"Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients","volume":"76","author":"Micozzi","year":"1990","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/39.3.383","article-title":"Teicoplanin versus flucloxacillin in the treatment of infection following burns","volume":"39","author":"Steer","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101754_bib46","first-page":"1205","article-title":"Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients","volume":"5","author":"Nucci","year":"1998","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1179\/joc.2000.12.4.326","article-title":"Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia","volume":"12","author":"Sidi","year":"2000","journal-title":"J Chemother"},{"issue":"8","key":"10.1016\/j.lanwpc.2025.101754_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.inf.0000059403.21440.2c","article-title":"Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children","volume":"22","author":"Wible","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.lanwpc.2025.101754_bib50","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.ASW.0000456631.20389.ae","volume":"27","author":"Tanus","year":"2014","journal-title":"Adv Skin Wound Care"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib51","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: a randomized trial","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.lanwpc.2025.101754_bib52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of Daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.lanwpc.2025.101754_bib53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/INF.0000000000002790","article-title":"Daptomycin for pediatric gram-positive acute hematogenous osteomyelitis","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib54","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib55","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.lanwpc.2025.101754_bib56","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40262-021-01027-9","article-title":"Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review","volume":"60","author":"Chung","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lanwpc.2025.101754_bib59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jpids\/piaa057","volume":"40","author":"Rybak","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.lanwpc.2025.101754_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3346\/jkms.2017.32.1.22","article-title":"Impact of initial vancomycin trough concentration on clinical and microbiological outcomes of methicillin-resistant {Staphylococcus} aureus bacteremia in children","volume":"32","author":"Yoo","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.lanwpc.2025.101754_bib61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamapediatrics.2019.1488","article-title":"Defining target vancomycin trough concentrations for treating Staphylococcus aureus infection in infants aged 0 to 90 days","volume":"173","author":"Gwee","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.lanwpc.2025.101754_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.lanwpc.2025.101754_bib63","doi-asserted-by":"crossref","first-page":"e109-","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children","volume":"4","author":"Le","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.lanwpc.2025.101754_bib64","article-title":"Clinical application value of pharmacokinetic parameters of vancomycin in children treated in the pediatric intensive care unit","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.lanwpc.2025.101754_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pedneo.2021.11.010","article-title":"Optimal exposure targets for vancomycin in the treatment of neonatal coagulase- negative Staphylococcus infection: a retrospective study based on electronic medical records","volume":"63","author":"Chen","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.lanwpc.2025.101754_bib66","doi-asserted-by":"crossref","first-page":"594562","DOI":"10.3389\/fphar.2020.594562","article-title":"Population pharmacokinetics and model-based dosing optimization of Teicoplanin in pediatric patients","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanwpc.2025.101754_bib67","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0000000000001456","article-title":"Evaluation of Teicoplanin Trough values after the recommended loading dose in children with associated safety analysis","volume":"36","author":"Yamada","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib68","series-title":"Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information","first-page":"404","author":"Yamada","year":"2022"},{"key":"10.1016\/j.lanwpc.2025.101754_bib69","first-page":"2318","article-title":"Age- and gender-related differences in teicoplanin levels in paediatric patients","volume":"68","author":"Strenger","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib70","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/jpids\/piab005","article-title":"Teicoplanin therapeutic drug monitoring and treatment outcomes in children with gram-positive infections","volume":"10","author":"Loane","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.lanwpc.2025.101754_bib71","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lanwpc.2025.101754_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ppul.20966","article-title":"Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis","volume":"44","author":"Santos","year":"2009","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02387-18","article-title":"Population pharmacokinetics and dosing optimizataion of linelozid in pediatric patients","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib74","doi-asserted-by":"crossref","first-page":"e02504-20","DOI":"10.1128\/AAC.02504-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in critically ill pediatric patients","volume":"65","author":"Yang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-022-03446-4","article-title":"Linezolid pharmacokinetics: a systematic review for the best clinical practice","volume":"79","author":"Heidari","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lanwpc.2025.101754_bib76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000086954.43010.63","article-title":"Linezolid pharmacokinetics in pediatric patients: an overview","volume":"22","author":"Jungbluth","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib77","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitroing may improve safety outcomes of long term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00895-21","article-title":"Population pharmacokinetics, exposure-response, and probability of target attainment analyses for tedizolid in adolescent patients with acute bacterial skin and skin structure infections","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib79","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/INF.0000000000001096","article-title":"Pharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescents","volume":"35","author":"Bradley","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101754_bib80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/INF.0000000000003030","article-title":"Pharmacokinetics and safety of single-dose Tedizolid Phosphate in children 2 to <12 years of age","volume":"40","author":"Arrieta","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib81","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1128\/AAC.01303-12","article-title":"Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model","volume":"56","author":"Lepak","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib82","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review","volume":"5","author":"Karageorgos","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.lanwpc.2025.101754_bib83","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/INF.0000000000000318","article-title":"Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age","volume":"33","author":"Bradley","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib84","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/INF.0b013e318160edfc","article-title":"Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections","volume":"27","author":"Abdel-Rahman","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of Daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of Daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib87","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib88","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e31820fc8e1","article-title":"Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg\/kg in children aged 2 to 6 years with suspected or proved gram-positive infections","volume":"30","author":"Abdel-Rahman","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanwpc.2025.101754_bib89","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcph.1576","article-title":"Pharmacokinetic\/Pharmacodynamic analysis of Daptomycin against Staphylococcus aureus and Enterococcus faecium in pediatric patients by Monte Carlo Simulation","volume":"60","author":"Wei","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101754_bib90","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jcph.2425","article-title":"Daptomycin dose optimization in pediatric Staphylococcus aureus bacteremia: a Pharmacokinetic\/Pharmacodynamic investigation","volume":"64","author":"Olney","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lanwpc.2025.101754_bib91","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s15010-011-0240-3","article-title":"Serum levels of daptomycin in pediatric patients","volume":"40","author":"Antachopoulos","year":"2012","journal-title":"Infection"},{"issue":"10","key":"10.1016\/j.lanwpc.2025.101754_bib92","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/archdischild-2021-323429","article-title":"Vancomycin-associated acute kidney injury epidemiology in children: a systematic review","volume":"107","author":"Williams","year":"2022","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101754_bib93","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijantimicag.2014.07.005","article-title":"Evaluation of teicoplanin concentrations and safety analysis in neonates","volume":"44","author":"Yamada","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.lanwpc.2025.101754_bib94","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jiac.2021.03.003","article-title":"A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections","volume":"27","author":"Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.lanwpc.2025.101754_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/00099228241242186","article-title":"Safety and treatment outcomes of infants and children treated with Daptomycin: six-year experience from a pediatric academic medical center","volume":"64","author":"Vonasek","year":"2025","journal-title":"Clin Pediatr"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101754_bib96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/phar.1872","article-title":"Clinical experience with Daptomycin in pediatrics","volume":"37","author":"Namtu","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lanwpc.2025.101754_bib97","series-title":"Vanuatu: essential Drug List 2014","year":"2024"},{"key":"10.1016\/j.lanwpc.2025.101754_bib98","series-title":"Solomon Islands: essential medicines list","year":"2017"},{"key":"10.1016\/j.lanwpc.2025.101754_bib99","series-title":"Fiji: essential medicines list 2015","year":"2024"},{"issue":"11","key":"10.1016\/j.lanwpc.2025.101754_bib100","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ppul.23827","article-title":"Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis","volume":"52","author":"Le","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.lanwpc.2025.101754_bib101","series-title":"Vanuatu National Essential Drug List 2014","year":"2014"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101754_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00048-19","article-title":"Antimicrobial resistance surveillance in low- and middle-income countries: progress and challenges in eight South Asian and Southeast Asian countries","volume":"33","author":"Gandra","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101754_bib103","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/jac\/dkaa065","article-title":"Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme: staphylococcus aureus, enterococcal and Gram-negative bacteraemia in Australia","volume":"75","author":"Campbell","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606525002937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606525002937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:39:33Z","timestamp":1773830373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606525002937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":103,"alternative-id":["S2666606525002937"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101754","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data and key evidence gaps","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101754"}}